Ionis Pharmaceuticals Inc (NASDAQ:IONS)‘s stock had its “market perform” rating reissued by stock analysts at Cowen and Company in a research note issued on Monday.

A number of other research analysts have also issued reports on IONS. Leerink Swann reissued an “outperform” rating and issued a $45.00 target price (down previously from $47.00) on shares of Ionis Pharmaceuticals in a report on Wednesday, May 17th. Needham & Company LLC reissued a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a report on Wednesday, May 17th. BMO Capital Markets reissued a “positive” rating and issued a $63.00 target price on shares of Ionis Pharmaceuticals in a report on Tuesday, February 14th. Piper Jaffray Companies set a $51.00 price target on Ionis Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 10th. Finally, Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $51.00 price target on the stock in a research note on Monday, February 13th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $42.13.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) traded up 0.96% on Monday, hitting $43.97. The stock had a trading volume of 182,589 shares. The stock’s market cap is $5.45 billion. The firm has a 50 day moving average of $43.64 and a 200 day moving average of $44.42. Ionis Pharmaceuticals has a 12 month low of $19.59 and a 12 month high of $57.00.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Tuesday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.13. The business had revenue of $110.30 million for the quarter, compared to analyst estimates of $86.03 million. Ionis Pharmaceuticals had a negative return on equity of 120.60% and a negative net margin of 77.30%. The company’s revenue for the quarter was up 199.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.52) earnings per share. On average, equities analysts forecast that Ionis Pharmaceuticals will post ($0.36) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/05/22/ionis-pharmaceuticals-ions-market-perform-rating-reiterated-at-cowen-and-company.html.

In other Ionis Pharmaceuticals news, SVP Patrick R. O’neil sold 650 shares of the business’s stock in a transaction on Monday, May 1st. The stock was sold at an average price of $48.75, for a total transaction of $31,687.50. Following the sale, the senior vice president now directly owns 10,299 shares in the company, valued at $502,076.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP C Frank Bennett sold 5,000 shares of the business’s stock in a transaction on Friday, March 3rd. The stock was sold at an average price of $55.00, for a total value of $275,000.00. Following the sale, the senior vice president now owns 19,788 shares in the company, valued at $1,088,340. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 57,275 shares of company stock worth $2,592,940. 1.86% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the company. Hanseatic Management Services Inc. purchased a new stake in Ionis Pharmaceuticals during the first quarter worth approximately $138,000. Massey Quick & Co. LLC purchased a new stake in Ionis Pharmaceuticals during the fourth quarter worth approximately $143,000. Westpac Banking Corp purchased a new stake in Ionis Pharmaceuticals during the first quarter worth approximately $171,000. Soros Fund Management LLC purchased a new stake in Ionis Pharmaceuticals during the fourth quarter worth approximately $206,000. Finally, Capstone Asset Management Co. increased its stake in Ionis Pharmaceuticals by 10.3% in the first quarter. Capstone Asset Management Co. now owns 5,148 shares of the company’s stock worth $207,000 after buying an additional 480 shares during the last quarter. Institutional investors own 87.76% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

12 Month Chart for NASDAQ:IONS

Receive News & Ratings for Ionis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.